Question → protocol → evidence
A structured route for diagnostic, monitoring, and infection-control teams to define assumptions, compare methods, run a pilot, and document limitations.
Innovation earns adoption when another qualified team can reproduce the test conditions, the method, the result, and the decision.
The lab starts with intended use and failure modes. Product enthusiasm comes after protocol versioning, operator training, interface verification, and an agreed acceptance threshold.
Three work cells
For IVD, record specimen matrix, limit of detection (LOD), coefficient of variation (CV), interference, reportable range, throughput, calibration interval, and comparator method. Higher analytical sensitivity can increase false-positive review burden when prevalence is low.
For monitoring, test essential performance, electromagnetic compatibility (EMC), IEC 60601-1-8 alarms, battery depletion, clock drift, identity, HL7 FHIR messaging, retry, and data reconciliation. Faster telemetry is not useful if timestamps or patient association fail.
For consumables and reusable workflows, map unique device identification (UDI), packaging, expiry, reprocessing validation, sterility assurance level (SAL), complaints, post-market surveillance (PMS), field actions, and disposal. Single-use and reusable paths shift risk rather than remove it.
Protocol completion
Percentages show process completion thresholds, not product performance.
Evidence anchors
Each mark is a document request, not a blanket assertion that every Abbott product follows the same regulatory pathway. A 510(k) substantial equivalence review differs from premarket approval (PMA), while design history file (DHF) and device master record (DMR) controls remain reference-specific.
Provide population or specimen, current comparator, expected volume, interface version, market, and decision threshold. No protected health information is needed for the initial review.
Request a protocol workshop